The primary stability of ultrashort residual proximal femur fixed with triangular fixation stem prosthesis: a comparative biomechanical study based on sawbones models.
IF 4.3 3区 工程技术Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
{"title":"The primary stability of ultrashort residual proximal femur fixed with triangular fixation stem prosthesis: a comparative biomechanical study based on sawbones models.","authors":"Ziwei Hou, Kai Zheng, Ming Xu, Xiuchun Yu","doi":"10.3389/fbioe.2024.1493738","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tumor resection near the proximal end of the femur and revision surgery of the distal femoral prosthesis may result in a very short bone segment remaining at the proximal end of the femur, known as ultrashort residual proximal femur (URPF). In this study, we propose a triangular fixation stem (TFS) prosthesis to improve the fixation of URPF. The aim of this research is to investigate the biomechanical properties of the TFS prosthesis and compare it with the conventional stem (CS) prosthesis through <i>in vitro</i> biomechanical experiments, providing preliminary biomechanical evidence for prosthetic fixation of URPF.</p><p><strong>Methods: </strong>A biomechanical study was conducted using Sawbones to explore initial stability. Twelve Sawbones were used to create a bone defect model, and prostheses were designed and fabricated to emulate TFS fixation and CS fixation structures. Axial compression and horizontal torsion experiments were performed on the fixed models using a mechanical testing machine, recording maximum displacement, maximum torque, and femoral strain conditions.</p><p><strong>Results: </strong>Under an axial compressive load of 2800 N, the overall displacement of the TFS group was 3.33 ± 0.58 mm, which was significantly smaller than that of the CS group (4.03 ± 0.32 mm, P = 0.029). The femoral samples of the TFS group demonstrated that the strain value alterations at the medial points 2, 3, 5, 6 and the lateral point 10 were conspicuously smaller than those of the conventional stem group (P < 0.05). Under torsional loads at levels of 1°, 3°, and 5°, the torques of the TFS group were 3.86 ± 0.69 Nm, 3.90 ± 1.26 Nm, and 4.39 ± 1.67 Nm respectively, all of which were significantly greater than those of the CS group (1.82 ± 0.82 Nm, P < 0.001; 2.05 ± 0.89 Nm, P = 0.016; 1.96 ± 0.50 Nm, P = 0.015 respectively).</p><p><strong>Conclusion: </strong>The TFS prosthesis improves fixation strength and reduces strain on the femur's proximal surface. Compared to CS fixation, it offers better resistance to compression and rotation, as well as improved initial stability.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"12 ","pages":"1493738"},"PeriodicalIF":4.3000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519860/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2024.1493738","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Tumor resection near the proximal end of the femur and revision surgery of the distal femoral prosthesis may result in a very short bone segment remaining at the proximal end of the femur, known as ultrashort residual proximal femur (URPF). In this study, we propose a triangular fixation stem (TFS) prosthesis to improve the fixation of URPF. The aim of this research is to investigate the biomechanical properties of the TFS prosthesis and compare it with the conventional stem (CS) prosthesis through in vitro biomechanical experiments, providing preliminary biomechanical evidence for prosthetic fixation of URPF.
Methods: A biomechanical study was conducted using Sawbones to explore initial stability. Twelve Sawbones were used to create a bone defect model, and prostheses were designed and fabricated to emulate TFS fixation and CS fixation structures. Axial compression and horizontal torsion experiments were performed on the fixed models using a mechanical testing machine, recording maximum displacement, maximum torque, and femoral strain conditions.
Results: Under an axial compressive load of 2800 N, the overall displacement of the TFS group was 3.33 ± 0.58 mm, which was significantly smaller than that of the CS group (4.03 ± 0.32 mm, P = 0.029). The femoral samples of the TFS group demonstrated that the strain value alterations at the medial points 2, 3, 5, 6 and the lateral point 10 were conspicuously smaller than those of the conventional stem group (P < 0.05). Under torsional loads at levels of 1°, 3°, and 5°, the torques of the TFS group were 3.86 ± 0.69 Nm, 3.90 ± 1.26 Nm, and 4.39 ± 1.67 Nm respectively, all of which were significantly greater than those of the CS group (1.82 ± 0.82 Nm, P < 0.001; 2.05 ± 0.89 Nm, P = 0.016; 1.96 ± 0.50 Nm, P = 0.015 respectively).
Conclusion: The TFS prosthesis improves fixation strength and reduces strain on the femur's proximal surface. Compared to CS fixation, it offers better resistance to compression and rotation, as well as improved initial stability.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.